ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

FDMT 4D Molecular Therapeutics Inc

25.475
0.085 (0.33%)
Last Updated: 09:19:20
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
4D Molecular Therapeutics Inc FDMT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.085 0.33% 25.475 09:19:20
Open Price Low Price High Price Close Price Previous Close
25.31 24.93 25.58 25.39
more quote information »

Recent News

Date Time Source Heading
5/01/202407:00GLOBE4DMT Announces Presentations at ARVO 2024 Annual Meeting
3/28/202407:00GLOBE4DMT Announces Update on Regulatory Interactions and..
3/04/202407:00GLOBE4DMT to Participate in Upcoming Investor Conferences
2/29/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/29/202416:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
2/29/202415:12EDGAR2Form 8-K - Current report
2/29/202415:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
2/21/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/14/202419:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202415:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202407:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/12/202420:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/12/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/12/202407:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
2/09/202415:56EDGAR2Form 8-K - Current report
2/08/202415:50EDGAR2Form 144 - Report of proposed sale of securities
2/08/202415:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2/08/202415:22EDGAR2Form 144 - Report of proposed sale of securities
2/07/202419:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/07/202418:42EDGAR2Form 3/A - Initial statement of beneficial ownership of..
2/06/202422:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
2/05/202416:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2/05/202415:35EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2/05/202415:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
2/03/202416:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
1/29/202407:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
1/25/202415:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/23/202415:50EDGAR2Form 144 - Report of proposed sale of securities
1/23/202407:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
1/08/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/05/202415:49EDGAR2Form 144 - Report of proposed sale of securities
1/04/202416:48EDGAR2Form 144 - Report of proposed sale of securities
1/04/202407:30EDGAR2Form 8-K - Current report
1/04/202407:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
1/03/202407:01GLOBE4DMT and Arbor Biotechnologies Establish Partnership to..
12/21/202311:31DJN4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
12/21/202307:00GLOBE4DMT Receives FDA Regenerative Medicine Advanced Therapy..
12/18/202316:16EDGAR2Form 144 - Report of proposed sale of securities
12/15/202316:24EDGAR2Form 144 - Report of proposed sale of securities
12/13/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/04/202307:00GLOBE4DMT to Present Interim 24 Week Data from Randomized Phase 2..
11/22/202315:20EDGAR2Form 8-K - Current report
11/15/202307:00GLOBE4DMT to Participate in Upcoming Investor Conferences
11/09/202315:23EDGAR2Form 8-K - Current report
11/09/202315:19GLOBE4DMT Reports Third Quarter 2023 Financial Results and..
11/01/202315:00GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..

Your Recent History

Delayed Upgrade Clock